.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Citi
Federal Trade Commission
Fish and Richardson
Farmers Insurance
Accenture
Cerilliant
QuintilesIMS
Novartis
Argus Health

Generated: November 21, 2017

DrugPatentWatch Database Preview

IMATINIB MESYLATE Drug Profile

« Back to Dashboard

What is the patent landscape for Imatinib Mesylate, and what generic Imatinib Mesylate alternatives are available?

Imatinib Mesylate is a drug marketed by Sun Pharma Global, Mylan Pharms Inc, Apotex Inc, and Teva Pharms Usa. and is included in four NDAs.

The generic ingredient in IMATINIB MESYLATE is imatinib mesylate. There are thirty-one drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the imatinib mesylate profile page.

Pharmacology for IMATINIB MESYLATE

Drug ClassKinase Inhibitor
Mechanism of ActionProtein Kinase Inhibitors

Medical Subject Heading (MeSH) Categories for IMATINIB MESYLATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharma Global
IMATINIB MESYLATE
imatinib mesylate
TABLET;ORAL078340-001Dec 3, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
IMATINIB MESYLATE
imatinib mesylate
TABLET;ORAL204285-001Aug 4, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
IMATINIB MESYLATE
imatinib mesylate
TABLET;ORAL204644-002Jun 21, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Teva Pharms Usa
IMATINIB MESYLATE
imatinib mesylate
TABLET;ORAL204285-002Aug 4, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Sun Pharma Global
IMATINIB MESYLATE
imatinib mesylate
TABLET;ORAL078340-002Dec 3, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
IMATINIB MESYLATE
imatinib mesylate
TABLET;ORAL204644-001Jun 21, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex Inc
IMATINIB MESYLATE
imatinib mesylate
TABLET;ORAL079179-002Aug 5, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex Inc
IMATINIB MESYLATE
imatinib mesylate
TABLET;ORAL079179-001Aug 5, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
McKesson
US Department of Justice
Argus Health
McKinsey
Moodys
Mallinckrodt
Novartis
Express Scripts
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot